title: German-Austrian recommendations for HIV-therapy in pregnancy and in HIV-exposed newborn - update 2005.
abstract: In Germany during the last years about 200-250 HIV infected pregnant women delivered a baby each year, a number that is currently increasing. To determine the HIV-status early in pregnancy voluntary HIV-testing of all pregnant women is recommended in Germany and Austria as part of prenatal care. In those cases, where HIV infection was known during pregnancy, since 1995 the rate of vertical transmission of HIV was reduced to 1-2%. - This low transmission rate has been achieved by the combination of anti-retroviral therapy of pregnant women, caesarean section scheduled before onset of labour, anti-retroviral post exposition prophylaxis in the newborn and refraining from breast-feeding by the HIV infected mother. To keep pace with new results in research, approval of new anti-retroviral drugs and changes in the general treatment recommendations for HIV infected adults, in 1998, 2001 and 2003 an interdisciplinary consensus meeting was held. Gynaecologists, infectious disease specialists, paediatricians, pharmacologists, virologists and members of the German AIDS Hilfe (NGO) were participating in this conference to update the prevention strategies. A third update became necessary in 2005. The updating process was started in January 2005 and was terminated in September 2005. The guidelines provide new recommendations on the indication and the starting point for therapy in pregnancies without complications, drugs and drug combinations to be used preferably in these pregnancies and updated information on adverse effects of anti-retroviral drugs. Also the procedures for different scenarios and risk constellations in pregnancy have been specified again. With these current guidelines in Germany and Austria the low rate of vertical HIV-transmission should be further maintained.
authors.affiliation: HIV-Ambulanz der Universitätskinderklinik Mannheim, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany. bernd.buchholz@kikli.ma.uni-heidelberg.de
authors.forename: Bernd
authors.initials: B
authors.lastname: Buchholz
authors.forename: M
authors.initials: M
authors.lastname: Beichert
authors.forename: U
authors.initials: U
authors.lastname: Marcus
authors.forename: T
authors.initials: T
authors.lastname: Grubert
authors.forename: A
authors.initials: A
authors.lastname: Gingelmaier
authors.forename: A
authors.initials: A
authors.lastname: Haberl
authors.forename: B
authors.initials: B
authors.lastname: Schmied
authors.forename: N
authors.initials: N
authors.lastname: Brockmeyer
mesh_terms: D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001317:Austria; D005858:Germany; D006287:Health Planning Guidelines; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011295:Prenatal Care
chemical_list: D019380:Anti-HIV Agents